مباشر

Clinical OMICsReporter’s Notebook: Are One-Shot Gene Editors Ready to Tackle Chronic Illness?FierceBiotechASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas FierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms BioPharma DiveRallyBio tries again for reverse merger, this time with Avenzo Endpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way Endpoints NewsEpigenetic editing shows promise against chronic hep B infections FierceBiotechASCO, Ryght AI team up for breast cancer trial site selection Clinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs Clinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side Effects Endpoints NewsShionogi wins US approval for first pill to prevent Covid following exposure BioWorldAppointments and advancements for June 1, 2026 BioWorldFinancings for June 1, 2026

FierceBiotech ١ يونيو ٢٠٢٦

At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms

For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncolog...

For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first look at its attempt to change that.